Involvement of Heme Oxygenase-1 in Neuropsychiatric and Neurodegenerative Diseases

Author(s): Vivian B. Neis, Priscila B. Rosa, Morgana Moretti, Ana Lucia S. Rodrigues*.

Journal Name: Current Pharmaceutical Design

Volume 24 , Issue 20 , 2018

Submit Manuscript
Submit Proposal

Abstract:

Heme oxygenase (HO) family catalyzes the conversion of heme into free iron, carbon monoxide and biliverdin. It possesses two well-characterized isoforms: HO-1 and HO-2. Under brain physiological conditions, the expression of HO-2 is constitutive, abundant and ubiquitous, whereas HO-1 mRNA and protein are restricted to small populations of neurons and neuroglia. HO-1 is an inducible enzyme that has been shown to participate as an essential defensive mechanism for neurons exposed to oxidant challenges, being related to antioxidant defenses in certain neuropathological conditions. Considering that neurodegenerative diseases (Alzheimer’s Disease (AD), Parkinson’s Disease (PD) and Multiple Sclerosis (MS)) and neuropsychiatric disorders (depression, anxiety, Bipolar Disorder (BD) and schizophrenia) are associated with increased inflammatory markers, impaired redox homeostasis and oxidative stress, conditions that may be associated with alterations in HO-levels/activity, the purpose of this review is to present evidence on the possible role of HO-1 in these Central Nervous System (CNS) diseases. In addition, the possible therapeutic potential of targeting brain HO-1 is explored in this review.

Keywords: Central nervous system, heme oxygenase-1, neurodegenerative diseases, neuropsychiatric disorders, neuroinflammation, oxidative stress.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 24
ISSUE: 20
Year: 2018
Page: [2283 - 2302]
Pages: 20
DOI: 10.2174/1381612824666180717160623
Price: $58

Article Metrics

PDF: 27
HTML: 5
PRC: 2